Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05503446
Other study ID # ERGO 71012
Secondary ID IRAS ID 310316
Status Recruiting
Phase N/A
First received
Last updated
Start date January 19, 2023
Est. completion date August 31, 2026

Study information

Verified date June 2023
Source University of Southampton
Contact Hasan Arshad, MBBS DM FRCP
Phone 44 23 8120 5232
Email p.turner@imperial.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Food allergy affects 1 in 30 children, and is the commonest trigger for life-threatening reactions (anaphylaxis) in this age group. It is a major public health issue, with practical implications for industry, education and healthcare systems. Oral immunotherapy (OIT) is an emerging treatment option, where small, increasing doses of a food allergen are used to cause "desensitisation", so food-allergic individuals no longer have symptoms when exposed to the trigger food. However, frequent allergic reactions during OIT (including anaphylaxis) are common, and can lead to patients having to stop treatment. In addition, food-allergic children usually dislike the taste of the food they are allergic too, which affects compliance and treatment success. There is a lack of longer-term data to inform cost-effectiveness analyses for OIT. The NATASHA study will recruit young people from age 6+ years with IgE-mediated peanut allergy, and young people aged 3+ years with IgE-mediated allergy to cow's milk, who will undergo oral immunotherapy for these allergens using real-world foods (taken carefully according to a standardised protocol under medical supervision). In addition to assessing efficacy and safety outcomes, we will also collect longer-term data to evaluate cost-effectiveness in the UK setting.


Recruitment information / eligibility

Status Recruiting
Enrollment 216
Est. completion date August 31, 2026
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender All
Age group 3 Years to 23 Years
Eligibility Inclusion Criteria: 1. Age 6-23 years with IgE-mediated peanut allergy, or age 3-23 years with IgE-mediated food allergy to cow's milk 2. Past history consistent with IgE-mediated allergy to the relevant allergen 3. Allergic to cumulative =1.44 g protein (of the specific allergen) at baseline DBPCFC, prior to treatment allocation 4. Written informed consent (for young people under 16, consent from the parent/legal guardian (AND assent from the young person when the young person is age 6+ years) Exclusion Criteria: 1. Required previous admission to an intensive care unit for management of an allergic reaction 2. Clinically significant chronic illness (other than asthma, rhinitis or eczema) 3. Moderate-severe eczema, defined as requiring more than once daily application of 1% hydrocortisone or equivalent topical calcineurin inhibitor as maintenance treatment despite appropriate use of emollients (eczema is not otherwise an exclusion criteria) 4. Poorly controlled asthma within the previous 3 months (as defined by clinician judgement with reference to the International Consensus On (ICON) Pediatric Asthma consensus), or asthma requiring treatment with >5 days oral corticosteroids within the previous 3 months 5. Previous history of eosinophilic oesophagitis 6. Undergoing subcutaneous or sublingual immunotherapy to respiratory allergens, and not yet established on maintenance dosing for at least 6 months 7. Undergoing allergen immunotherapy for food allergy and within the first year of treatment 8. In CM-allergic children under consideration for desensitisation to CM: - currently consuming CM-containing products other than extensively-heated milk in baked foods (e.g. biscuits, cakes) - significant symptoms of non-IgE-mediated CM allergy within the previous 12 months 9. Taking prebiotic or probiotic supplements and unwillingness to discontinue 10. Subjects receiving anti-IgE therapy, oral immunosuppressants, beta-blocker or Angiotensin Converting Enzyme (ACE) inhibitor 11. Tolerance to cumulative =1.44 g food protein at initial DBPCFC during screening 12. Objective allergic reaction to =4mg cow's milk protein or ½ Reese's puff in peanut-allergic children, during screening 13. Objective reaction to the placebo at screening DBPCFC 14. Past or current medical issue, participation in another clinical trial or other consideration, which, in the opinion of the investigator, may pose additional risks from study participation, interfere with compliance or otherwise impact on the quality or interpretation of study data 15. Pregnancy 16. Direct personal or commercial relationship with a member of the local study team directly involved with the conduct of the trial 17. Unwilling or unable to fulfil study requirements, including the requirement for appropriate supervision following dosing at home)

Study Design


Intervention

Other:
Peanut in common foods or supermarket-sourced cow's milk (CM)
Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol

Locations

Country Name City State
United Kingdom University of Hospitals of Leicester NHS Trust Leicester
United Kingdom Imperial College Healthcare NHS Trust London
United Kingdom Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle
United Kingdom Sheffield Children's Hospital NHS Foundation Trust Sheffield
United Kingdom University Hospital Southampton NHS Foundation Trust Southampton

Sponsors (3)

Lead Sponsor Collaborator
University of Southampton Imperial College London, Natasha Allergy Research Foundation

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy and effectiveness The proportion of participants in intervention arms (combined) versus control arm (by allergen) who, following 9-12 months of OIT (or standard care, for controls):
tolerate at least 1 gram of food protein (discrete dose, approximately 4-6 peanuts, or 30ml of CM) AND
demonstrate a minimum 10-fold increase in the maximum tolerated dose (defined as the highest dose not causing dose-limiting symptoms) at the end-of-updosing double-blind, placebo-controlled food challenge (DBPCFC), compared to baseline DBPCFC
9-12 months
Secondary Safety: adverse events i. Proportion of participants experiencing study-related adverse events (excluding mild, transient oropharyngeal symptoms) in active vs control arms, by allergen ii. Other safety outcomes: rate of anaphylaxis (and adrenaline [epinephrine] use), withdrawals due to intervention, by allergen iii. Adverse events (excluding mild, transient oropharyngeal symptoms) specifically occurring at updosing visits, in the home versus in-hospital updosing groups, by allergen 24 months
Secondary Health-related quality of life (HRQL) as assessed by the Food Allergy Quality of Life Questionnaire (FAQLQ) Change in HRQL score assessed using validated questionnaire (Food Allergy Quality of Life Questionnaires (FAQLQ), from baseline at the following timepoints post allocation: 3, 6, end of induction (9-12 months), 18 and 24 months, in i. Participants ii. Parent/carers (if participants aged =17 years)
The tools to be used are:
- FAQLQ: as per Muraro et al, Allergy 2014; 69:845-853. A higher score is associated with a greater impact on quality of life, as per the cited reference.
24 months
Secondary Health-related quality of life (HRQL) as assessed by EQ5D Change in quality of life assessment assessed using EQ5D, from baseline at the following timepoints post allocation: 3, 6, end of induction (9-12 months), 18 and 24 months, in i. Participants ii. Parent/carers (if participants aged =17 years)
The tools to be used are:
- EQ5D: a standardised measure of health-related quality of life developed by the EuroQol Group to provide a simple, generic questionnaire for use in clinical and economic appraisal and population health surveys (see https://euroqol.org/ for detailed instructions on use)
24 months
Secondary Health-related quality of life (HRQL) as CHU9D Change in quality of life assessment assessed using CHU9D, from baseline at the following timepoints post allocation: 3, 6, end of induction (9-12 months), 18 and 24 months, in i. Participants ii. Parent/carers (if participants aged =17 years)
The tools to be used are:
- CHU9D - a paediatric generic preference-based measure of health-related quality of life suitable for 7 to 17 year olds. (see https://licensing.sheffield.ac.uk/product/CHU-9D for detailed instructions on use)
24 months
Secondary Adherence to dietary avoidance Adherence to dietary avoidance between intervention and control arms (by allergen, and between allergens) as determined by number of accidental reactions reported by each participant, during the duration of the study 24 months
Secondary Adherence to treatment Adherence to daily OIT dosing by allergen, expressed as a the proportion of doses taken divided by the number of doses which should have been taken by each participant. 24 months
Secondary Immunological outcomes: change in skin prick test wheal Change in immunological measures (skin prick test wheal (mm diameter) to commercial allergen extract, performed according to national guidelines) at baseline vs 12 months vs 24 months, between active and control arms (by allergen) 24 months
Secondary Immunological outcomes: change in allergen-specific serum antibody profile Change in immunological measures (specific Immunoglobulin E (IgE) to specific allergen) measured by ImmunoCAP (kUA/l) at baseline vs 12 months vs 24 months, between active and control arms (by allergen) 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05667610 - Immune-supportive Diet and Gut Permeability in Allergic Children N/A
Recruiting NCT05440643 - Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Phase 1
Terminated NCT03849079 - Validation of the HYPONUT Product N/A
Completed NCT02979600 - Clinical and Biological Efficacy of Peanut Oral Immunotherapy N/A
Completed NCT01955109 - Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Phase 2
Completed NCT01950533 - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Recruiting NCT04415593 - High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety N/A
Active, not recruiting NCT04511494 - Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Active, not recruiting NCT04881773 - Oral Low Doses Tolerance INduction Study for Peanuts
Completed NCT03682770 - Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Phase 2
Terminated NCT03703791 - Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents Phase 3
Completed NCT02916446 - Safety Study of Viaskin Peanut to Treat Peanut Allergy Phase 3
Active, not recruiting NCT02402231 - Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Phase 2
Completed NCT03337542 - AR101 Real-World Open-Label Extension Study Phase 3
Recruiting NCT05476497 - Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects Phase 1
Completed NCT03648320 - The Grown Up Peanut Immunotherapy Study N/A
Completed NCT03292484 - Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Phase 3
Completed NCT03852342 - Reactive Doses and Times During Oral Food Challenge to Peanut
Recruiting NCT05138757 - Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Phase 1/Phase 2